Introduction
Carbonic anhydrases (CAs, EC 4.2.1.1) are zinc metalloenzymes that catalyze the reversible hydration of carbon dioxide (CO 2 ) to generate bicarbonate anion (HCO 3 -) and a proton (H + ), Scheme 1. with an extracellularly oriented active site. They are predominantly expressed in poorly vascularized hypoxic tumors and have minimal expression in healthy cells. 3 Tumor cells experience elevated metabolism, and thus increased acid production, compared to healthy cells. [3] [4] [5] [6] If this acid-load is allowed to accumulate then intracellular pH (pH i ) would fall and disrupt critical biological functions.
Recent evidence has demonstrated that cell-generated CO 2 , in addition to lactic acid, is predominantly responsible for the removal of excess acid from tumor cells. 4 CO 2 is freely membrane permeable and rapidly exits metabolically active tumor cells via passive diffusion. 5 The role of CA IX and XII is to catalyze the hydration of tumor generated CO 2 to form HCO 3 -and H + (Scheme 1), the net effect is to trap H + extracellularly, lowering extracellular pH (pH e ) whilst maintaining normal pH i . [3] [4] [5] This process favours tumor growth and invasion, allowing hypoxic tumor cells to survive and proliferate. 4, 7 The importance of modulating pH in the hypoxic tumor microenvironment underpins a strong case to develop well designed small-molecule inhibitors of CA IX and XII for application as chemical probes. These compounds are needed to appraise the potential of cancer-associated CAs as a possible mode for therapeutic intervention in cancer. 1, 8 The extracellular active site location of CA IX and XII together with their expression in hypoxic cancer cells (overexpression) compared to healthy cells (minimal expression) improves the odds for the development of tumor selective CA inhibitors.
The implied target for small molecule drug design of CA inhibitors is the CA active site Zn 2+ cation, and both sulfonamide (-SO 2 NH 2 ), and less frequently, sulfamate (-OSO 2 NH 2 ) zinc binding groups feature in the structure of many small molecule CA inhibitors. 1, 9 In the last few years our group has established a novel approach to targetting the inhibition of CA IX and XII using carbohydrate-based small molecules. [10] [11] [12] [13] [14] [15] Drug-like carbohydrate-based molecules are now viewed as a vast but relatively untapped source of potential new therapeutics. 16, 17 We have demonstrated that through appending sugar moieties to the Ar-SO 2 NH 2 zinc binding pharmacophore of classical CA inhibitors we were able to deliver potent inhibitors for CA IX and XII in vitro. 18 More recently we reported a new class of compound that incorporates a sulfonamide moiety directly attached to the anomeric centre of a mono-or disaccharide i.e.
[sugar]-SO 2 NH 2 . 19 The value of these anomeric sulfonamides was three-fold -first they were novel chemical entities, second they lacked the classical aromatic component of classical CA inhibitors, and third, they allowed us to tune the physicochemical properties of the inhibitor towards selective inhibition of CA IX and XII owing to the glycoconjugates compromised ability to diffuse across cell membranes. The CA inhibition activity of these compounds was however only moderate with K i s in the micromolar range. In the present contribution we extend our focus on modulating structureproperty relationships (SPR) of CA inhibitors whilst delivering novel compounds with good CA inhibition activity and isozyme selectivity. Specifically we present the design, synthesis and biological evaluation of carbohydrate-based sulfamates of the motif [sugar]-OSO 2 NH 2 .
Results and Discussion
Compound Design. Topiramate (2,3:4,5-bis-O-(l-methylethy1idene)-6-D-fructopyranosyl sulfamate, TPM) is a billion dollar drug that is marketed worldwide for the treatment of epilepsy and migraine. 20 TPM is a fructose sulfamate and is an excellent inhibitor of CAs in vitro. 21 The chemical structure of TPM has two isopropylidine groups masking four secondary hydroxyl groups, with the primary hydroxyl group sulfamoylated, Figure 1 .
T o pi rama t e ( TPM ) Figure 1 . Structure of topiramate, a fructose sulfamate CA inhibitor.
The sulfamate compounds 7-18 of this study were derived from the monosaccharides D-glucose, Dgalactose, D-mannose and methyl α-glucopyranoside and the disaccharide maltose, Figure 2a . The sulfamate group is on the C-6 (or C-6' for maltose) primary hydroxyl group. Compounds 13 and 18 are O-methyl glycosides, while the remaining hydroxyls of compounds are either acylated (7) (8) (9) (10) (11) (12) (13) or fully deprotected to provide free sugars (14) (15) (16) (17) (18) Common scaffold is coloured by atom type (red, grey, blue and yellow), variable acetate groups are coloured black.
In addition to inspiration from the impressive pharmaceutical pedigree of the carbohydrate-sulfamate drug TPM, the design principle towards the target molecules 7-18 was to develop a family of compounds that provided incremental coverage of chemical property space. The application of esters as a prodrug strategy to mask polar hydroxyl groups is prevalent across medicinal chemistry and chemical biology. 22 Such prodrugs take advantage of hydrolysis by nonspecific esterases to unmask the hydroxyl groups in vivo, the prodrugs often survive the GI tract and may be absorbed into the blood stream where they are hydrolyzed by plasma enzymes. 23 Esterification of the hydroxyl groups of carbohydrates has been used to modulate the membrane permeability and downstream activity of carbohydrate-based molecules. 24, 25 In this study we explore the acetyl, propionyl and butryl acyl groups, each are expected to be substrates of esterases. The five different sugar types of this study were chosen to present a selection of molecular shapes with subtle stereochemical differences to the CA enzyme active site and contribute to building valuable SAR. This is demonstrated by an overlay of stick models of sulfamates 7, 10, 12 and 13, Figure 2b . All compounds 7-18 preserve the sulfamate zinc binding group that is critical for good CA inhibition. protecting groups were removed with NaI/TMSCl to unmask the C-6 primary hydroxyl groups, providing precursor compounds 4-6. The yield for detritylation using this method is low compared to more traditional conditions, however these reagents avoid acyl group migration and the associated mixture of products. 27, 28 Selective sulfamoylation of the now free C-6 hydroxyl groups of 4-6 with sulfamoyl chloride (generated in situ from formic acid and chlorosulfonylisocyanate) gave target sulfamates 7-9. 29 Lastly, the O-acetate groups of the carbohydrate moiety of the sulfamates were removed using Zemplen's conditions 30 The synthesis of the target maltose sulfamates 12 and 17 followed an analogous strategy to the monosaccharides, however several additional steps were needed to accommodate selectivity in the presence of the two primary alcohols of the disaccharide, Scheme 3. First the 4',6'-O-benzylidine acetal of maltose is prepared, and the remaining six hydroxyl groups acetylated. Removal of the benzylidene acetal with aqueous acetic acid provides a diol precursor that is manipulated similarly to the procedure outlined for the monosaccharides. All target sulfamates 7-18 were spectroscopically characterized using 1D and 2D NMR ( 1 H, 13 C, gCOSY, gHSQC). The characterization data were consistent with the target structures, with a characteristic broad singlet for the sulfamate protons (O-SO 2 NH 2 ) for all compounds observed at δ 7.40-7.60 ppm in d 6 -DMSO. Carbonic Anhydrase Inhibition. The enzyme inhibition data for sulfamates 7-18 as well as the sulfamate drug TPM were determined by assaying the CA catalyzed hydration of CO 2 , Table 1 . 31 Enzyme inhibition data for the physiologically dominant CA I and II, and tumor-associated CA IX and XII were obtained. Isozyme selectivity ratios for 7-18 and TPM are also provided, Table 1 . Off-target CA isozyme I. The sulfamate compounds were micromolar inhibitors of the off-target CA I isozyme, with K i s ranging from 0.86 -12.6 µM. Inhibition at CA I is weaker than for the other CA isozymes. The TPM inhibition profile behaves similarly, also showing poorer inhibition of CA I (K i = 250 nM) than for the other CA isozymes. The structural variability provided by the three different acyl groups had no remarkable impact on structure-activity relationships (SAR) at CA I with the K i values for
Notable however was that the free sugar glucose analogue 14 was a better CA I inhibitor (
than the acylated analogues 7-9. The disaccharide maltose derivatives 12 (K i = 12.6 µM) and 17 (K i = 8.74 µM) were weaker inhibitors than the monosaccharides.
Off-target CA isozyme II. CA II is a much more efficient enzyme than CA I and inhibition of this isozyme is largely responsible for side effects associated with clinically used CA inhibitors. 1 TPM is a very potent CA II inhibitor with a K i of 5.0 nM. Compound 11, the acetylated mannose derivative, was the only potent CA II inhibitor of the novel sulfamates (K i = 11.3 nM). The remaining monosaccharide sulfamates were moderately active at this off-target enzyme, with K i s ranging from 66 -307 nM. Given the sole structural difference between compound 11 and compounds 7 and 10 is the stereochemistry of one position on the monosaccharide moiety this is intriguing SAR that may assist to identify further opportunities in CA inhibitor design. As for CA I, the maltose derivatives 12 (K i = 754 nM) and 17 (K i = 513 nM) were the weakest inhibitors at CA II, while the three different acyl groups of 7-9 also had little impact on SAR at CA II.
Cancer-associated CA isozymes IX and XII. Sulfamates 11, 13, 14 and 18 were good CA IX inhibitors with inhibition constants clustered below 10 nM (K i s 7.9 -9.0 nM) with very good selectivity over the off-target CA I (124-to 674-fold) and up to 14-fold selectivity against CA II, the latter is very good and contrasts with the behaviour of TPM which is non-selective for CA II. At hCA IX compounds 7-10, 15
and 16 had K i s ranging from 53-86 nM similar to TPM (K i of 58 nM). These compounds generally had good selectivity over CA I (up to 112-fold) but were non-selective over CA II. At CA XII sulfamates were generally more effective inhibitors than for other isozymes, with K i s for compounds 13-16 ranging from 7.3 -9.5 nM, compared to TPM with a K i of 3.8 nM. Compounds 10, 14-16 had >10-fold selectivity over CA II and >70-fold selectivity over CA I. With the exception of 14, these compounds were also selective over CA IX (5.6 to 8. showed no isozyme selectivity, while the reverse is true for the C-6 sulfamates, some of which display excellent selectivity for the cancer-associated CAs. Using protein X-ray crystallography we demonstrated that the shape of the anomeric sulfonamide ligands resulted in less than optimal CA active site interactions. 19 The design of the new compounds of this study address this limitation and has provided better performing compounds. 
Structure-Property Relationships (SPR).
The incorporation of variable acyl protecting groups onto the carbohydrate core of glucose derivatives 7-9, 13, 14 and 18 has encapsulated a range of LogP and topological polar surface area (TPSA) values, Table 3 . Manipulating these physicochemical parameters is a useful way to refine druggability and notably this coverage of chemical property space was achieved with retention of the underlying glucose sulfamate core. 33, 34 Values for TPSA, calculated LogP (cLogP), molecular weight (MW) and ligand efficiency (LE) for TPM and all glucose sulfamates are provided in LE represents the relationship between a compounds potency and its MW and is now emerging as an important metric to guide drug discovery campaigns. The LE value is indicative of the prospects for druggability properties such as bioavailability, stability and solubility and permits the comparison of the relative quality of different leads. 37 Perola recently reported an analysis of 60 lead/drug pairs, 38 the findings from this analysis revealed a number of useful threshold values to guide medicinal chemists, notably that 90% of drug leads had LE >12.4, while 90% of drugs had LE > 14.7. All sulfamates of this study have LE similar to, or far exceeding these thresholds at the cancer-associated CAs, Table 3 .
Compound 14, a free sugar, represents the core scaffold of all the novel sulfamates of this study and has the highest LE (>30) at both CA IX and CA XII. The other free sugar of this study, compound 18 was also a very efficient ligand, with LE >20 at both CA IX and CA XII. The precursors to 14, compounds 8 and 9, have LE values > 14 and >13, respectively, indicative of good drug leads and supporting our strategy with masking the hydroxyl groups. 
Conclusions
In summary, our study has delivered novel, potent and selective carbohydrate-based sulfamates that inhibit cancer-associated CAs. Compounds comprised a sulfamate zinc binding group appended to the C-6 hydroxyl of a panel monosaccharides or the C-6' hydroxyl of maltose. The SAR and SPR properties for these compounds, with variable acyl protecting groups, has provided a new approach to CA inhibitor development. Parent sulfamates are predicted to have good oral bioavailability, yet target selectively the active site of extracellular CA IX and XII over intracellular CAs once processed by esterases.
Collectively this library of carbohydrate-based sulfamates exhibits biopharmaceutical properties that render these compounds potentially valuable for applications as chemical probes in medicinal chemistry.
Experimental Section
Chemistry. All starting materials and reagents were purchased from commercial suppliers. Solvents were dried prior to use, or purchased anhydrous from Sigma-Aldrich. 
